Hayes Don, Jennerich Ann L, Coleman Ryan D, Abston Eric, Adamson Gregory T, Berger John T, Cohen Sarah P, Cooper David S, Eghtesady Pirooz, Fynn-Thompson Francis, Grady R Mark, Hon Stephanie M, Hoopes Charles W, Jewell Teresa, Lewthwaite Hayley, Liu Michelle F, McGiffin David C, Mullen Mary P, Qureshi Athar M, Morales David L S
Am J Respir Crit Care Med. 2025 Feb;211(2):157-173. doi: 10.1164/rccm.202410-1901ST.
Pulmonary hypertension in children is progressive with wide variability in prognosis. This document provides an evidence-based clinical practice guideline for the management of children with progressive pulmonary hypertension despite optimal therapy. A multidisciplinary panel identified pertinent questions regarding the management of children with pulmonary hypertension that has progressed despite optimal therapy, conducted systematic reviews of the relevant literature, and applied the Grading of Recommendations, Assessment, Development and Evaluation approach to develop clinical recommendations. After reviewing the research evidence, the panel considered the balance of desirable (benefits) and undesirable (harms and burdens) effects of the interventions in each proposed question. Valuation of our main outcomes was also considered, together with resources required, equity, acceptability, and feasibility. Recommendations were developed for or against interventional strategies specific to children with pulmonary hypertension that has progressed despite optimal therapy. Although there is a growing population of children with pulmonary hypertension, there is a striking lack of empirical evidence regarding management of those whose disease has progressed despite optimal pharmacotherapy. The panel formulated and provided the rationale for clinical recommendations for or against interventional strategies on the basis of this limited empirical evidence, coupled with expert opinion, to aid clinicians in the management of these complex pediatric patients. In addition, we identified important areas for future research.
儿童肺动脉高压呈进行性发展,预后差异很大。本文档为尽管接受了最佳治疗但仍患有进行性肺动脉高压的儿童提供了基于证据的临床实践指南。一个多学科小组确定了有关尽管接受了最佳治疗但仍患有肺动脉高压的儿童管理的相关问题,对相关文献进行了系统评价,并应用推荐分级、评估、制定与评价方法来制定临床推荐。在审查研究证据后,该小组考虑了每个拟议问题中干预措施的有益(益处)和有害(危害和负担)影响之间的平衡。还考虑了对我们主要结局的评估,以及所需资源、公平性、可接受性和可行性。针对尽管接受了最佳治疗但仍患有进行性肺动脉高压的儿童,制定了支持或反对特定干预策略的推荐。尽管患有肺动脉高压的儿童数量不断增加,但对于那些尽管接受了最佳药物治疗但疾病仍进展的儿童的管理,明显缺乏经验证据。该小组基于这一有限的经验证据并结合专家意见,制定并提供了支持或反对干预策略的临床推荐理由,以帮助临床医生管理这些复杂的儿科患者。此外,我们确定了未来研究的重要领域。